Late Gastrointestinal Morbidity After Three-Dimensional Conformal Radiation Therapy for Prostate Cancer Fades With Time in Contrast to Genitourinary Morbidity

This publication has 27 references indexed in Scilit:

• Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
  International Journal of Radiation Oncology*Biology*Physics, 2006
• Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects
  British Journal of Cancer, 2005
• Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer
  Radiotherapy and Oncology, 2004
• RTOG 94-06: Is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?
  International Journal of Radiation Oncology*Biology*Physics, 2003
• Changes in Treatment Volume of Hormonally Treated and Untreated Cancerous Prostate and its Impact on Rectal Dose
  Acta Oncologica, 2003
• Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study
  International Journal of Radiation Oncology*Biology*Physics, 1999
• Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin
  New England Journal of Medicine, 1997
• R: A Language for Data Analysis and Graphics
  Journal of Computational and Graphical Statistics, 1996
• Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)
  International Journal of Radiation Oncology*Biology*Physics, 1995
• Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen
  Cancer, 1993